Whole-exome sequencing in familial Parkinson disease

JAMA Neurology

Volumn 73, Issue 1, 2016, Pages 68-75

  Farlow, Janice L ^a   Robak, Laurie A ^b,c   Hetrick, Kurt ^d   Bowling, Kevin ^e   Boerwinkle, Eric ^b,f   Coban Akdemir, Zeynep H ^b   Gambin, Tomasz ^b   Gibbs, Richard A ^b   Gu, Shen ^b   Jain, Preti ^e,g   Jankovic, Joseph ^b   Jhangiani, Shalini ^b   Kaw, Kaveeta ^b,c   Lai, Dongbing ^a   Lin, Hai ^h   Ling, Hua ^d   Liu, Yunlong ^a   Lupski, James R ^b,c   Muzny, Donna ^b   Porter, Paula ^b,c   Pugh, Elizabeth ^d   White, Janson ^b   Doheny, Kimberly ^d   Myers, Richard M ^e   Shulman, Joshua M ^b,c   Foroud, Tatiana ^a   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Texas Children's Hospital   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Department of Medicine   (United States)

^h INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE IDENTIFICATION; GENE REPLICATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; TNK2 GENE; TNR GENE; UNITED STATES; AGED; DNA SEQUENCE; EXOME; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; MIDDLE AGED; PARKINSONIAN DISORDERS; PROCEDURES;

PROTEIN TYROSINE KINASE; TENASCIN; TENASCIN R; TNK2 PROTEIN, HUMAN;

ADULT; AGED; COHORT STUDIES; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, DNA; TENASCIN;

EID: 84954288030     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.3266     Document Type: Article

References (45)

1. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003; 299(5604): 256-259.
2. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44 (4): 601-607.
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276 (5321): 2045-2047.
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676): 605-608.
5. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674): 1158-1160.
6. Vilariño-Güell C,Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease [published correction appears in Am J Hum Genet. 2011;89(2): 347]. Am J Hum Genet. 2011;89(1): 162-167.
7. Zimprich A, Benet-Pagès A, StruhalW, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89(1): 168-175.
8. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12(11): 745-755.
9. NicholsWC, Pankratz N, Hernandez D, et al; Parkinson Study Group-PROGENI Investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005;365(9457): 410-412.
10. Klein C, Chuang R, Marras C, Lang AE. The curious case of phenocopies in families with genetic Parkinson's disease. Mov Disord. 2011;26(10): 1793-1802.
11. Cady J, Allred P, Bali T, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77(1): 100-113.
12. NeriM, BovolentaM, Scotton C, et al. Whole exome sequencing filtered by novel candidate genes as tool for gene discovery in a recessive family with Parkinson and ataxia. Neuromuscul Disord. 2012;22(9-10): 810-810.
13. Vilariño-Güell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014;23(7): 1794-1801.
14. Edvardson S, Cinnamon Y, Ta-Shma A, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One. 2012;7(5): E36458. doi: 10.1371/journal.pone.0036458.
15. Köroglu C., Baysal L, Cetinkaya M, Karasoy H, Tolun A. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord. 2013;19(3): 320-324.
16. Nuytemans K, Bademci G, Inchausti V, et al. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology. 2013; 80(11): 982-989.
17. NicholsWC, Pankratz N, Uniacke SK, et al. Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson's disease families. J Med Genet. 2002;39(7): 489-492.
18. Pankratz N, NicholsWC, Uniacke SK, et al; Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1): 124-135.
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55 (3): 181-184.
20. Ashburner M, Ball CA, Blake JA, et al; The Gene Ontology Consortium. Gene ontology: Tool for the unification of biology. Nat Genet. 2000;25(1): 25-29.
21. Gene Ontology Consortium. Gene Ontology Consortium: Going forward. Nucleic Acids Res. 2015; 43(database issue): D1049-D1056.
22. 1000 Genomes. A deep catalog of human genetic variation. http: //www.1000genomes.org/about. Accessed October 20, 2015.
23. National Heart, Lung, and Blood Institute. NHLBI Grand Opportunity Exome Sequencing Project (ESP). https: //esp.gs.washington.edu/drupal/. Accessed October 20, 2015.
24. J. Craig Venter Institute. SIFT (Sorting Intolerant From Tolerant). http: //sift.jcvi.org/. Accessed October 20, 2015.
25. Prediction of Functional Effects of Human nsSNPS. PolyPhen-2 (Polymorphism Phenotyping v2). http: //genetics.bwh.harvard.edu/pph2/. Accessed October 20, 2015.
26. Mutation Tasting. MutTaster (Mutation Taster). http: //www.mutationtaster.org/. Accessed October 20, 2015.
27. Sidow Lab. GERP (Genome Evolutionary Rate Profiling). http: //mendel.stanford.edu/SidowLab /downloads/gerp/. Accessed October 20, 2015.
28. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3): 310-315.
29. Petrovski S,Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 2013;9(8): E1003709. doi: 10.1371/journal.pgen.1003709.
30. Broad Institute. Genome Analysis Toolkit (GATK). https: //www.broadinstitute.org/gatk/. Accessed October 20, 2015.
31. La Torre A, del Rio JA, Soriano E, Ureña JM. Expression pattern of ACK1 tyrosine kinase during brain development in the mouse. Gene Expr Patterns. 2006;6(8): 886-892.
32. Ureña JM, La Torre A, Martínez A, et al. Expression, synaptic localization, and developmental regulation of Ack1/Pyk1, a cytoplasmic tyrosine kinase highly expressed in the developing and adult brain. J Comp Neurol. 2005; 490(2): 119-132.
33. La Torre A, del Mar Masdeu M, Cotrufo T, et al. A role for the tyrosine kinase ACK1 in neurotrophin signaling and neuronal extension and branching. Cell Death Dis. 2013;4: E602. doi: 10.1038/cddis .2013.99.
34. Hitomi Y, Heinzen EL, Donatello S, et al. Mutations in TNK2 in severe autosomal recessive infantile onset epilepsy. Ann Neurol. 2013;74(3): 496-501.
35. Howlin J, Rosenkvist J, Andersson T. TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res. 2008;10(2): R36.
36. GalisteoML, Yang Y, Ureña J, Schlessinger J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A. 2006;103(26): 9796-9801.
37. Pesheva P, Spiess E, Schachner M. J1-160 and J1-180 are oligodendrocyte-secreted nonpermissive substrates for cell adhesion. J Cell Biol. 1989;109(4, pt 1): 1765-1778.
38. Jakovcevski I, Miljkovic D, Schachner M, Andjus PR. Tenascins and inflammation in disorders of the nervous system. Amino Acids. 2013;44(4): 1115-1127.
39. Anlar B, Gunel-Ozcan A. Tenascin-R: Role in the central nervous system. Int J Biochem Cell Biol. 2012;44(9): 1385-1389.
40. QuadriM, Yang X, Cossu G, et al. An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics. 2015;16(1): 55-64.
41. Healy DG, Falchi M, O'Sullivan SS, et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol. 2008;7(7): 583-590.
42. Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6): 752-757.
43. McDonnell SK, Schaid DJ, Elbaz A, et al. Complex segregation analysis of Parkinson's disease: TheMayo Clinic Family Study. Ann Neurol. 2006;59(5): 788-795.
44. KurzM, Alves G, Aarsland D, Larsen JP. Familial Parkinson's disease: A community-based study. Eur J Neurol. 2003;10(2): 159-163.
45. Elbaz A, Grigoletto F, Baldereschi M, et al; EUROPARKINSON Study Group. Familial aggregation of Parkinson's disease: A population-based case-control study in Europe. Neurology. 1999;52(9): 1876-1882.